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Objective. The objective of this study is to compare ovarian function and surgical outcomes between pa-
tients affected by benign uterine pathologies submitted to total laparoscopic hysterectomy (TLH) plus
salpingectomy and women in which standard TLH with adnexal preservation was performed.
Methods.We retrospectively compared data of 79 patients who underwent TLH plus bilateral salpingectomy
(group A), with those of 79women treated by standard TLHwithout adnexectomy (sTLH) (group B). Ovarian re-
serve modiﬁcation, expressed as the difference between 3 months post-operative and pre-operative values of
Anti-Müllerian Hormone (AMH), Follicle Stimulating Hormone (FSH), Antral Follicle Count (AFC), mean ovarian
diameters and Peak Systolic Velocity (PSV),was recorded for each patient. For each surgical procedure, operative
time, variation of hemoglobin level (ΔHb), postoperative hospital stay, postoperative return to normal activity,
and complication rate were recorded as secondary outcomes.
Results.According to our post-hoc analysis, this equivalence study resulted to have a statistical power of 96.8%.
Signiﬁcant difference was not observed between groups with respect to ΔAMH (p = 0.35), ΔFSH (p = 0.15),
ΔAFC (p = 0.09), Δmean ovarian diameters (p = 0.57) and ΔPSV (p = 0.61). In addition, secondary outcomes
such as operative time (p = 0.79),ΔHb (p = 0.41), postoperative hospital stay (p = 0.16), postoperative return
to normal activity (p = 0.11) and complication rate also did not show any signiﬁcant difference.
Conclusions. The addition of bilateral salpingectomy to TLH for prevention of ovarian cancer in women who
do not carry a BRCA1/2 mutations do not show negative effects on the ovarian function. In addition, no periop-
erative complications are related to the salpingectomy step in TLH.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Ovarian cancer is still the most frequent cause of death by gyne-
cological malignancy for women in developed countries. To date,
all attempted ovarian cancer screening strategies have failed, proba-
bly because this disease represents different kinds of cancers [1]. Re-
cently, a new classiﬁcation of ovarian cancer in two different types of
cancer has been introduced, where type II ovarian tumors (includingGynaecology, “Magna Graecia”
o, Italy. Fax: +39 0961883234.
-ND license.the so called High-Grade Serous Cancer, HGSC) are considered the
most frequently diagnosed, aggressive, genetically instable and
often disseminated kind of disease [2].
One of themore important ﬁnding in last decade of gynecologic on-
cology is the conﬁrmed theory that types II tumors derive from the ep-
ithelium of the Fallopian tube, whereas clear cell and endometrioid
tumors derive from endometrial tissue thatmigrate to the ovary by ret-
rograde menstruation [3].
These observations are mainly collected from women that carry
BRCA1/2 mutations and underwent prophylactic salpingo-
oophorectomy, in which most of the incidentally diagnosed in
situ carcinomas or intraepithelial precursors of cancers (STIC) were
detected not in the ovary but in the ﬁmbrial end of the fallopian tube
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carrying BRCA mutations, thanks to an extended protocol of pathologic
examination of the Fallopian tubes (SEE-FIM) of patients operated for
sporadic HGSC [7–10].
Consequently it is probably time to ask ourselves whether it is still
ethically justiﬁed not to inform our patients about the possibility of a
new preventive strategy based on prophylactic salpingectomy at the
time of surgery for benign pathologies.
As a matter of fact, in the general population, prophylactic
salpingectomy might reduce the risk of sporadic ovarian cancer re-
ducing at the same time the risk of premature death due to cardiovas-
cular disease seen in women subjected to salpingo-oophorectomy
before the onset of natural menopause [11,12].
Bilateral salpingectomy with ovarian preservation should be con-
sidered in a cost-beneﬁt analysis, as the best preventive strategy for
women with low risk of ovarian cancer (not carrying BRCA muta-
tions), although it is mandatory to assess the effects and complica-
tions associated with it. Nevertheless, the effects of salpingectomy
on ovarian functions are still controversial. To the best of our knowl-
edge, there are no strong evidences on the effect of salpingectomy on
surgical outcomes of a standard hysterectomy.
The goal of this study is to evaluate ovarian function and surgical
outcomes of patients with benign uterine pathologies that were
subjected to TLH combined with bilateral salpingectomy against those
who were subjected to standard TLH with adnexal preservation.Materials and methods
Patient's selection
The procedures used in this retrospective case-control study were
in accordance with the guidelines of the Helsinki Declaration on
Human Experimentation and the Good Clinical Practice (CGP). The
approval by the Institutional Review Board was not required due to
the retrospective manner of the study. However, a written consent
was obtained from all patients for the use of their clinical data prior
to the beginning the study. All patients were previously instructed
about the recent acknowledgment on high grade serous cancer and
its suspected origin, and they signed a written consent before surgery.
All patients who underwent TLH for abnormal uterine bleeding
(AUB) related to benign pathology at the Department of Obstetrics
and Gynecology, Magna Graecia University of Catanzaro, between
September 2010 and September 2012, were identiﬁed as group A.
In all these women, ovaries were preserved but prophylactic
salpingectomy was added. Data for these patients were compared
with those of women treated by standard TLH (sTLH) between Sep-
tember 2008 and September 2010, matched for uterine weight
(gr), measured after surgery (group B). Clinical and surgical data
were extracted from charts and collected for each patient.
We excluded data of patients older than 50 years, with a family his-
tory of ovarian cancer, BRCA positive, basal FSH value of >20 IU/mL
and/or E2 levels >60 pg/mL, presence of menopausal symptoms,
irregular (cycle-to-cycle variation over 12 months >20 days or
presence of any breakthrough bleeding) menstrual cycles, hormone
replacement treatment and/or hormonal contraception for the last
3 months, history of previous uterine or ovarian surgeries, and imag-
ing suggestive of ovarian cyst or tubal pathology at transvaginal
ultrasound.
Patients in Group A underwent TLH and complete excision of the
fallopian tubes bilaterally. Salpingectomy was performed by coagula-
tion and section of the tube, beginning from the very distal ﬁmbrial
end, carefully preserving the ovarian vascularization, and proceeding
toward the uterine cornu. Thus, fallopian tubes were removed together
with the uterus. In group B, all patients had been subjected to sTLHwith
adnexal preservation.Clinical outcomes
For each patient in both groups, ovarian reservemodiﬁcation before
and after surgery was recorded as primary outcome. In particular,
according to our standard protocol, onemonth before and threemonths
after laparoscopy, all patients in our Unit are usually included in a pro-
gram of assessment of ovarian reserve and distance from menopause.
On days 1 to 4 of menstrual cycles serum anti-Müllerian hormone
(AMH, ng/mL), Follicle Stimulating hormone (FSH, IU/L) and Estradiol
(E2, pg/mL) were evaluated and a transvaginal ultrasound examination
(Aloka ProSound SSD-3500 Ultrasound Machine—MGMedical System)
to assess basal and antral follicle number [all ovarian folliclesmeasuring
3 mm to 10 mm on the both ovaries are counted (AFC, n)], mean
ovarian diameter [measured in the largest crossectional sagittal
view of the ovaries, evaluating the two perpendicular diameters
(mm)], and peak systolic velocity [measured by color Doppler ultra-
sound, on stromal blood vessels away from the ovarian capsule and
utero-ovarian ligament, (PSV, cm/s)] was carried out by the same ex-
perienced ultrasonographist responsible for the ambulatory of ovar-
ian reserve.
Blood samples were obtained by venipuncture and centrifuged,
within 30 min of collection, for 10 min at 4 °C at 3500 rpm, to separate
the serum. Each serum sample was then stored at −80 °C for subse-
quent analysis of AMH, FSH and E2 levels. AMH Gen II Elisa assay kit
(Beckman) was used to measure serum AMH levels, according to
manufacturer's instruction. The lowest detection limit was 1 ng/mL
and the intra and interassay coefﬁcients of variation were respectively
below 3.4% and 4.0%. The ECLIA method was used to measure FSH and
E2 levels in serum, using a COBAS e411 Roche auto-analyzer. The lowest
detection limit for FSHwas 0.1 IU/L, with the intra- and interassay coef-
ﬁcients of variation were below 2.6% and above 3.5%. The lowest detec-
tion limit for E2 was 18.4 pmol/L, with the intra- and interassay
coefﬁcients of variation were of 2% and 3%, respectively.
After laparoscopic hysterectomy, due to the absence of menstrual
ﬂow, patients are instructed to identify their early follicular phase by
consulting their past menstrual diary and recognizing the rapid de-
crease of self-reported “ﬂuid retention” impression, indicated by a feel-
ing of bloating, edema, and/or nicturia, in the days of the expected
menses [13]. Ovarian reserve is therefore re-evaluated when early fol-
licular phase is conﬁrmed by the presence of serum E2 level b60 pg/
mL and progesterone (P) level b1 ng/mL, in conjunction with ultra-
sound evaluation (absence of a dominant follicle >10 mm in any of
the ovaries). Ovarian reserve modiﬁcation is deﬁned as the difference
(expressed as Δ) between post-operative and pre-operative values of
AMH, FSH, AFC, mean ovarian diameters and PSV.
For each surgical procedure, operative time (min), variation of he-
moglobin level (ΔHb, g/dL), postoperative hospital stay (days), postop-
erative return to normal activity (days), complication rate (%) were
recorded as secondary outcomes. Return to normal activity was deﬁned
as the time taken for the patient to achieve the same level of activity as
to which they were capable preoperatively following discharge from
hospital. This might includeminor discomfort and the use of simple an-
algesic medication. Complete recovery was not measured because of
the large variation in this non-quantitative measure. Many patients
were not employed and therefore the time to return to employment
was not used as an end point [14].
Statistical methods
For categorical variables, the χ2 test or Fisher exact test was applied
as appropriate. The normal distribution of continuous variables was
evaluated using the Kolmogrov–Smirnov test. Since continuous vari-
ables resulted in normal distribution, data were expressed as mean
and standard deviation (SD). Continuous variables were analyzed
using the independent samples t-test, or the paired t-test for repeated
measurements as appropriate. All statistical analyses were performed
Table 2
Primary outcomes measures.





Δ AMH (ng/mL) −0.06 ± 0.1 −0.08 ± 0.1 0.35
Δ FSH (mIU/ml) 1.3 ± 1.1 1.0 ± 0.8 0.15
Δ AFC (n) −0.27 ± 0.6 −0.14 ± 0.3 0.09
Δ Mean ovarian diameters (mm) −0.25 ± 0.8 −0.19 ± 0.6 0.57
Δ PSV (cm/s) −0.31 ± 1.9 −0.19 ± 1.0 0.61
All data are expressed as mean and SD.
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used as a threshold for deﬁning difference as statistically signiﬁcant.
Post-hoc power analysis
Aprior analysis conducted on our data demonstrated a post-operative
AMH levels average decrease of 9% in women submitted to total lap-
aroscopic hysterectomy with adnexal preservation (standard proce-
dure). Assuming a 10% decrease with this procedure, and a maximal
clinically acceptable decreasing for equivalence of 15% in AMH levels
in women after salpingectomy, a sample of at least 69 patients per
group would have given 95% power and a one-sided signiﬁcance
level of 10%. In our study, therefore, given a sample size of 79 pa-
tients in each group, power model resulted of 96.8%.
Results
After discriminating for inclusion/exclusion criteria, we selected
79 premenopausal women treated by TLH with salpingectomy
(Group A) and of other 79 patients submitted to sTLH (Group B).
As detailed in Table 1, at baseline there was no signiﬁcant differ-
ence between the two groups for anthropometric characteristics, ob-
viously including uterine weight. Similarly, no statistically signiﬁcant
differences were observed between the two groups in AMH (0.49 ±
0.4 in group A vs. 0.51 ± 0.5 ng/mL in B; p = 0.80), FSH (12.3 ± 5.2
vs. 11.4 ± 4.6 mIU/mL in groups A and B, respectively; p = 0.27),
AFC (4.4 ± 1.2 vs. 4.0 ± 2.0 in groups A and B, respectively; p =
0.13), mean ovarian diameters (26.7 ± 4.1 vs. 25.8 ± 3.8 mm in
groups A and B, respectively; p = 0.16) and PSV (10.1 ± 2.1 vs.
9.5 ± 2.0 cm/s in groups A and B, respectively; p = 0.07). E2 levels
were statistically signiﬁcant between the two groups, but these values
were not clinically relevant, because they were always lower than
60 pg/mL.
Table 2 shows the primary outcome measures. As detailed in the
materials and methods, the ovarian reserve modiﬁcation is
expressed as the Δ between post-operative and pre-operative values
of AMH, FSH, AFC, mean ovarian diameters and PSV. Statistically or
clinically signiﬁcant difference was not observed between groups
for parameters evaluating the ovarian reserve after surgery. Both
groups were homogeneous for ΔAMH (−0.06 ± 0.1 vs. −0.08 ±
0.1 ng/mL in groups A and B, respectively; p = 0.35), ΔFSH (1.3 ±
1.1 vs. 1.0 ± 0.8 mIU/mL in groups A and B, respectively; p =
0.15), ΔAFC (−0.27 ± 0.6 vs. −0.14 ± 0.3 in groups A and B, re-
spectively; p = 0.09), Δmean ovarian diameters (−0.25 ± 0.8 vs.
−0.19 ± 0.6 mm in groups A and B, respectively; p = 0.57) and
ΔPSV (−0.31 ± 1.9 vs. −0.19 ± 1.0 cm/s in groups A and B, re-
spectively; p = 0.61).
Regarding the secondary outcomes, there was no statistically nor
clinically signiﬁcant difference between groups A and B for operative
time, ΔHb, postoperative hospital stay, postoperative return to nor-
mal activity and complication rate (%). Data is provided in Table 3.Table 1
Main anthropometric and hormonal measures at baseline.





Age (years) 45.8 ± 2.4 46.5 ± 2.9 0.10
BMI (kg/m2) 22.8 ± 1.8 23.3 ± 1.7 0.13
Uterine weight (g) 328.9 ± 115.0 316.9 ± 149.0 0.62
AMH (ng/mL) 0.49 ± 0.4 0.51 ± 0.5 0.80
FSH (mIU/mL) 12.3 ± 5.2 11.4 ± 4.6 0.27
E2 (pg/mL) 22.8 ± 15.9 28.1 ± 15.1 0.04
AFC (n) 4.4 ± 1.2 4.0 ± 2.0 0.13
Mean ovarian diameters (mm) 26.7 ± 4.1 25.8 ± 3.8 0.16
PSV (cm/s) 10.1 ± 2.1 9.5 ± 2.0 0.07
All data are expressed as mean and SD.Discussion
In this studywe demonstrate that ovarian function and surgical out-
comes in patients submitted to TLH for benign uterine pathologies are
notmodiﬁed by the addiction of bilateral salpingectomy to the standard
technique. Both hormonal and ultrasonographic parameters, indeed,
are not signiﬁcantly altered when salpingectomy is performed together
with our surgical standard technique.
Our surgical technique carefully preserves the ovarian blood sup-
ply, ensured by an arcade-like anastomosis system formed by ovari-
an artery and the tubal branch of the uterine artery at the junction of
the mesosalpinx and the mesovary, close to the hilum of the ovary.
The attention to blood supply when adding bilateral salpingectomy
to TLH may explain our positive results in terms of post-operative
ovarian function, since an intact blood ﬂow is essential to a normal
ovarian steroid hormone synthesis.
Preservation of the ovarian function is important both in the
pre-menopausal age and in the post-menopause, due to the effective
prevention of bone resorption, guaranteed by the intact ovaries
[15–17]. Furthermore, surgical menopause increases long-term risk
of psychosexual, cognitive and cardiovascular dysfunctions [18–20]
and incidence of fatal and non-fatal coronary heart diseases [21].
These data suggest that, at least for premenopausal women with
no genetic risk for ovarian cancer, oophorectomy at the time of hys-
terectomy should be approached with great caution [21,22].
Considering the new acquisitions in the ﬁeld of HGSC, our improved
understanding of its pathogenesis surely opens new opportunities for
prevention, in which every gynecologic surgeons, not only oncologist,
can play an important role by performing bilateral salpingectomy dur-
ing any kind of hysterectomy (laparoscopic, laparotomic or vaginal) or
at the time of surgical sterilization [23].
The preservation of the Fallopian tubes during hysterectomy is a
surgical strategy with no known beneﬁts and conversely, the
blind-ended remnants may give rise to complications, such as
hydrosalpinx [24,25], which often requires recurring surgeries.
Thus, removal of the tubes rather than the ovaries could be efﬁcient
in preventing HGSC, potentially avoiding issues of long-term surgical
complication and hormonal function.
According to the existing literature, however, whether bilateral
salpingectomy impairs ovarian reserve is still amatter of debate. Animal
studies shows that there is no impairment [25-27] albeit there areTable 3
Secondary outcomes measures.





Operative time (min) 81.7 ± 14.8 83.3 ± 18.6 0.79
Δ Hb (g/dL) 1.1 ± 0.9 1.2 ± 0.7 0.41
Postoperative hospital stay
(days)
2.5 ± 0.8 2.7 ± 0.8 0.16
Postoperative return to normal
activity (days)
15.0 ± 4.4 13.9 ± 4.8 0.11
Complication rate (%) 0 0 –
All data are expressed as mean and SD.
451M. Morelli et al. / Gynecologic Oncology 129 (2013) 448–451conﬂicting results on ovarian response to medical induction of super-
ovulation in patients treated by salpingectomy [28,29].
Recently, Sezik Mekin et al. investigated the effect of total
salpingectomy during hysterectomy in a small sample of 12 patients
compared to other 12 treated by partially salpingectomy. In their pa-
tients, hormonal parameters were unchanged after both strategies,
but ovarian stromal bloodﬂow appeared to be decreased in both groups
compared to baseline values [30]. The small statistical power of the in-
vestigation, however, limited the reliability of their data.
To the best of our knowledge, the present study is the ﬁrst com-
prehensive comparison of the outcomes of TLH with and without bi-
lateral salpingectomy, evaluating the ovarian function and surgical
parameters in a large population of patients. Despite the retrospective
fashion of the study design, according to our post-hoc analysis, we
obtained a power model of 96.8%. This result allows us to ensure
our data with a good statistical reliability.
Our demonstration of the safety of adding bilateral salpingectomy
to TLH can be the ﬁrst step to declaring that the new proposed strategy
to prevent ovarian cancer does not cause harm to our patients, allowing
us to respect our ﬁrst medical rule, primum non nocere. Although the
new data on the pathogenesis of ovarian cancer cannot be considered
100% veriﬁed,wewonder if it is ethically justiﬁed not to counsel our pa-
tients about the possibility of a simple preventive strategy, such as
salpingectomy [31].
Considering that in developed countries hysterectomy is the second
most frequently performed surgical intervention amongwomenof repro-
ductive age, and in USA about one-third of all 60-year-old women have
had a hysterectomy [32], it is clear that a strong rational exists to justify
the British Columbia Ovarian Cancer Prevention Project. It encourages
prophylactic salpingectomy and estimates up to 50% reduction in ovarian
cancer deaths after 20 years, up to 20% through salpingectomy at time of
hysterectomy, up to 20% through salpingectomy instead of tubal ligation
and up to 20% through risk‐reducing bilateral salpingo-oophorectomy in
patients with BRCA mutations [33].
Moreover, by extending the practice of performing SEE-FIM [10] in
all salpingectomy specimens, it will be possible to provide a deﬁnitive
population-based assessment of the frequency and risk of STIC in
risk-reducing specimens in low risk womenwith BRCA-negative family
background.
Another important short term objective will be to carefully char-
acterize the histopathological and molecular features of the precursor
lesions found in the fallopian tubes, to enable us to ﬁnd the diagnostic
tools for deﬁning a “medium risk” category of women (without the
BRCA mutations) in which we hypothesize either a preventive bilat-
eral salpingectomy once they have accomplished their reproductive
desire or a medical chemoprevention.
In conclusion, our demonstration that ovarian function and surgi-
cal outcomes in patients submitted to TLH are not modiﬁed by adding
salpingectomy to the standard technique is the ﬁrst answer to the dis-
cordance about the degree of inﬂuence on ovarian reserve related to
tubal surgery. We demonstrate that if salpingectomy is performed
with great care by preserving blood vessels integrity in the proximity
of the ovarian hilum and in the context of the mesosalpinx, patients
will not have negative effects in on their ovarian function. In addition,
in our experience, no perioperative complications associated with the
procedure are attributable to salpingectomy alone. Salpingectomy
can be deﬁned as a simple and safe surgical procedure, not harmful
for our patients, in terms of ovarian function and surgical outcomes.
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